The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Exelixis Inc

Nasdaq: EXEL
Last

(U.S.) $1.76

Today's change+0.04 +2.33%
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.
 

Exelixis Inc

Nasdaq: EXEL
Last

(U.S.) $1.76

Today's change+0.04 +2.33%
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.

Exelixis Inc crosses above 20-day moving average

Exelixis Inc closed up sharply Wednesday, rallying (U.S.)$0.04 or 2.33% to (U.S.)$1.76 and crossing above its 20-day moving average. Over the last five days, shares have gained 3.53%, but are down 71.29% for the last year to date. Shares have underperformed the S&P 500 by 84.53% during the last year.

Key company metrics

  • Open(U.S.) $1.72
  • Previous close(U.S.) $1.72
  • High(U.S.) $1.76
  • Low(U.S.) $1.68
  • Bid / Ask-- / --
  • YTD % change-71.29%
  • Volume1,090,735
  • Average volume (10-day)1,397,709
  • Average volume (1-month)1,983,501
  • Average volume (3-month)3,915,955
  • 52-week range(U.S.) $1.35 to (U.S.) $8.41
  • Beta2.48
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.47
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-1,272.72%

Exelixis Inc has a net profit margin of -1,272.72%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.23%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue6754
Total other revenue--------
Total revenue6754
Gross profit6654
Total cost of revenue1000
Total operating expense58687064
Selling / general / administrative10161514
Research & development44515550
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)4000
Other operating expenses, total--------
Operating income-52-62-65-60
Interest income (expense), net non-operating-12-12-12-12
Gain (loss) on sale of assets------0
Other--------
Income before tax-63-73-75-71
Income after tax-63-73-75-71
Income tax, total--000
Net income-63-73-75-71
Total adjustments to net income--------
Net income before extra. items-63-73-75-71
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-63-73-75-71
Inc. avail. to common incl. extra. items-63-73-75-71
Diluted net income-63-73-75-71
Dilution adjustment0000
Diluted weighted average shares195195192184
Diluted EPS excluding extraordinary itemsvalue per share-0.32-0.38-0.39-0.38
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.30-0.37-0.39-0.38